Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | -1.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.68 | N/A | -1.91% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to long-term goals.
Management did not provide specific guidance for the upcoming quarters.
The company remains focused on its long-term growth strategy despite the current EPS miss.
Neurocrine Biosciences reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.58%, possibly due to overall market conditions or investor sentiment. The lack of revenue data and guidance may leave investors uncertain about the company's immediate future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MATSON INC